Three widely held misconceptions reflect and contribute to polarization. For each, there’s a kernel of truth that appears to support the misconception, but the reality is clear.
A new study from researchers at Environmental Influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health shows how a stress scale developed to identify who was most at-risk of needing mental health support during the pandemic has the potential to evaluate traumatic stress reactions to ongoing large-scale threats.
A study based on 211 pregnant women given the antiviral drug nirmatrelvir and ritonavir (Paxlovid) during pregnancy for acute COVID-19 infections shows no increased risk of adverse events in the women or their babies and a reduced risk of complications called the maternal morbidity and mortality index (MMMI).
The findings, published today in Nature Medicine, suggest the drug is safe to use in pregnancy and is effective in reducing MMMI risk but not COVID-related hospitalizations.
New research has identified 38 direct-to-consumer businesses marketing stem-cell treatments and exosome therapies for COVID-19 infections and, especially, long COVID, despite lacking approval by US Food and Drug Administration and other regulatory body in the United States. Descriptions of the businesses and an analysis of their marketing strategies are published in Stem Cell Reports.
